Clinical Trials

The goal of the ADAPT study is to study whether using two drugs, carfilzomib and belatacept, together can lower the number of plasma cells in “highly sensitized” people on the kidney transplant waiting list.

The goal of ATTAIN is to study whether using two drugs, daratumumab and belatacept, together can lower the number of plasma cells in “highly sensitized” people on the kidney transplant waiting list.

The goal of the VIBRANT trial is to determine if treating lupus nephritis with VIB4920 in addition to standard therapy is more effective than treating lupus nephritis with standard therapy alone.

The goal of CONTROL-RA is to see how the experimental study drug, VIB4920, affects control of rheumatoid arthritis (RA).

A study about the safety of daratumumab in patients with antiphospholipid syndrome (APS), and its effectiveness at reducing the antiphospholipid antibodies that cause APS.

DESIGNATE is a clinical study to identify a safe, metabolically favorable, dosing regimen for siplizumab in patients with type 1 diabetes mellitus.

This trial investigates the landscape of blood T lymphocytes in patients with active forms of multiple sclerosis. The goal of the study is to demonstrate T cell receptor (TCR) patterns that are specific for disease activity at the patient level and then to use this “TCR signature” to follow regulation of auto reactive T cells, particularly during tolerance induction.

This clinical trial is being performed in collaboration with the Finnish Diabetes Prediction and Prevention project and is studying individuals in various stages of prediabetes who receive intranasal insulin as part of a secondary prevention trial. The ITN is funding the support of additional laboratory studies to identify biomarkers that can predict the onset of type 1 diabetes and to learn more about the natural history of the disease.

This study aims to evaluate the safety and tolerability of a 5 mg dose of the study drug, NBI-5788, for treatment of relapsing-remitting multiple sclerosis patients. A prior phase 2 trial conducted with this drug demonstrated suggestive evidence of treatment benefit with a 5 mg dose of NBI-5788.

This study seeks to optimize and standardize an existing assay which allows the T-cell response directed against in transplant recipients who undergo immune tolerance induction. This study employs a rapid laboratory test that would enable the transplant physicians to look at the patient's immune response to this model virus.